Raphael Pharmaceutical (RAPH) Free Cash Flow (2020 - 2025)
Raphael Pharmaceutical (RAPH) reported Free Cash Flow of $46000.0 for Q4 2025, up 174.19% on a YoY basis from $16776.5 in Q4 2024, and up 370.59% sequentially from -$17000.0 in Q3 2025.
Raphael Pharmaceutical (RAPH) Free Cash Flow (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 6 years of Free Cash Flow data on file, last reported at $46000.0 in Q4 2025.
- For the quarter ending Q4 2025, Free Cash Flow rose 174.19% year-over-year to $46000.0; the trailing twelve-month figure through Dec 2025 stood at -$210000.0 (up 60.6% YoY), and the FY2025 full-year result was -$210000.0, up 60.53% from the prior year.
- Free Cash Flow grew to $46000.0 in Q4 2025, from -$17000.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $46000.0 in Q4 2025 to a low of -$704000.0 in Q4 2021.
- A 5-year average of -$206200.0 and a median of -$191000.0 in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow plunged 386.59% in 2023 and soared 174.19% in 2025, its largest moves.
- Tracing RAPH's Free Cash Flow over 5 years: stood at -$704000.0 in 2021, then jumped by 60.65% to -$277000.0 in 2022, then soared by 68.23% to -$88000.0 in 2023, then climbed by 29.55% to -$62000.0 in 2024, then jumped by 174.19% to $46000.0 in 2025.
- Business Quant data shows RAPH's Free Cash Flow at $46000.0 in Q4 2025, -$17000.0 in Q3 2025, and -$30000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | 46,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Mar 31, 2025 | -209,000.00 |
| Mar 31, 2025 | -209,000.00 |
| Dec 31, 2024 | -62,000.00 |
| Dec 31, 2024 | -62,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Jun 30, 2024 | -218,000.00 |
| Jun 30, 2024 | -218,000.00 |
| Mar 31, 2024 | -173,000.00 |
| Mar 31, 2024 | -173,000.00 |
| Dec 31, 2023 | -88,000.00 |
| Dec 31, 2023 | -88,000.00 |
| Sep 30, 2023 | -501,000.00 |
| Sep 30, 2023 | -501,000.00 |